SELEURL PHARMACIE NOUVELLE : revenue, balance sheet and financial ratios

SELEURL PHARMACIE NOUVELLE is a French company founded 28 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in SAINT-PAUL (97423), this company of category PME shows in 2018 a revenue of 1.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SELEURL PHARMACIE NOUVELLE (SIREN 413994740)
Indicator 2025 2024 2023 2022 2021 2020 2018 2017
Revenue N/C N/C N/C N/C N/C N/C 1 535 104 € 1 607 453 €
Net income 107 597 € 75 149 € 9 760 € 134 016 € 100 865 € 61 405 € 44 093 € 95 751 €
EBITDA N/C N/C N/C N/C N/C N/C 70 956 € 145 643 €
Net margin N/C N/C N/C N/C N/C N/C 2.9% 6.0%

Revenue and income statement

In 2025, SELEURL PHARMACIE NOUVELLE generates positive net income of 108 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2025: 96 k€ -> 108 k€.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

107 597 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 42%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 53%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

42.116%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

52.799%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

57.2%

Solvency indicators evolution
SELEURL PHARMACIE NOUVELLE

Sector positioning

Debt ratio
42.12 2025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Good -13 pts over 3 years

In 2025, the debt ratio of SELEURL PHARMACIE NOUVELLE (42.12) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
52.8% 2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average +9 pts over 3 years

In 2025, the financial autonomy of SELEURL PHARMACIE NOUVELLE (52.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 135.65. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

135.65

Liquidity indicators evolution
SELEURL PHARMACIE NOUVELLE

Sector positioning

Liquidity ratio
135.65 2025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Average

In 2025, the liquidity ratio of SELEURL PHARMACIE NOUVELLE (135.65) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.

Operating WCR (2025) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2025) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

0 j

Supplier credit (2025) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

0 j

Inventory turnover (2025) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
SELEURL PHARMACIE NOUVELLE

Positioning of SELEURL PHARMACIE NOUVELLE in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 277 transactions of similar company sales in 2025, the value of SELEURL PHARMACIE NOUVELLE is estimated at 1 709 191 € (range 1 159 865€ - 2 681 956€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
277 transactions
1159k€ 1709k€ 2681k€
1 709 191 € Range: 1 159 865€ - 2 681 956€
NAF 5 année 2025

Valuation method used

Net Income Multiple
107 597 € × 15.9x = 1 709 191 €
Range: 1 159 865€ - 2 681 956€

Only this financial indicator is available for this company.

Valuation evolution

How is this estimate calculated?

This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare SELEURL PHARMACIE NOUVELLE with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about SELEURL PHARMACIE NOUVELLE

What is the revenue of SELEURL PHARMACIE NOUVELLE ?

The revenue of SELEURL PHARMACIE NOUVELLE in 2018 is 1.5 M€.

Is SELEURL PHARMACIE NOUVELLE profitable?

Yes, SELEURL PHARMACIE NOUVELLE generated a net profit of 108 k€ in 2025.

Where is the headquarters of SELEURL PHARMACIE NOUVELLE ?

The headquarters of SELEURL PHARMACIE NOUVELLE is located in SAINT-PAUL (97423), in the department La Reunion.

Where to find the tax return of SELEURL PHARMACIE NOUVELLE ?

The tax return of SELEURL PHARMACIE NOUVELLE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SELEURL PHARMACIE NOUVELLE operate?

SELEURL PHARMACIE NOUVELLE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.